Press Release & Investor Presentation

October 27, 2026 BSE Limited National Stock Exchange of India Limited Floor 25, P.J. Tower Exchange Plaza Dalal Street, Fort Bandra Kurla Complex Mumbai - 400 001 Bandra (E), Mumbai - 400 051 Scrip Code: 543271 Trading Symbol: JUBLINGREA Sub: Press Release and Presentation on the financials and operational performance of the Company for the quarter and half year ended September 30, 2026 Ref.: Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 Dear Sir/Madam, In continuation of our letter dated October 14, 2026, regarding the Investors Conference Call scheduled to be held on Tuesday, October 27, 2026, please find enclosed the Press Release and Presentation that will be discussed during the meeting. The above details will also be available on the website of the Company at www.jubilantingrevia.com. We request you to take the same on record. Thanking you, Yours faithfully, For Jubilant Ingrevia Limited Deepanjali Gulati Company Secretary & Compliance Officer Encl.: as above Jubilant Ingrevia Limited 1A, Sector 16A, Noida – 201301, India Tel.: +91 120 4361000 www.jubilantingrevia.com PRESS RELEASE NOIDA, Tuesday, October 27th, 2026 JUBILANT INGREVIA LIMITED – Q2’FY27 RESULTS Particulars1 Q2'FY26 Q1'FY27 Q2'FY27 Q-o-Q Y-o-Y H1'FY26 H1'FY27 Y-o-Y Total Revenue 1,121 1,300 1,394 7% 24% 2,159 2,695 25% Total EBITDA 146 209 221 6% 51% 300 431 44% EBITDA Margin (%) 13% 16% 16% 14% 16% PAT after Exceptional Items 69 106 111 5% 61% 145 217 50% PAT Margin (%) 6% 8% 8% 7% 8% Basic and Diluted EPS (Rs.) 4.4 6.7 7.1 6% 61% 9.2 13.8 50% 1. All figures are in Rs Crore unless otherwise stated The Board of Jubilant Ingrevia Limited met today to approve financial results for the quarter and half year ended September 30th, 2026. Commenting on the Company’s performance, Mr. Shyam S Bhartia, Chairman and Mr. Hari S Bhartia, Co- Chairman, Jubilant Ingrevia Limited said: “We are pleased to report sustained strong growth momentum in Q2 FY27, with revenue growing by 24% YoY, and EBITDA growing by 51% YoY, reflecting disciplined execution across our businesses. Our quarterly EBITDA has more than doubled in three years, reflecting the successful execution of our Pinnacle strategy and disciplined cost management. This momentum was also reflected in our strong H1 performance, with revenue increasing by 25% and EBITDA by 44%. We are delighted to have signed an agreement to acquire a 40% stake in ZettaOne Technologies Limited, marking our entry into the EDMS space, which will help us in offering an integrated value proposition to our customers in Electronics/Semicon sectors”. Markets Update: Amid continued geopolitical uncertainties, volumes remained stable, while firmer crude prices supported improved realizations. The quarter also witnessed higher input and utility costs, which partially offset the benefits of improved pricing. The Pharmaceutical sector continued to grow on the back of steady volumes driven by sustained demand for intermediates. The Agrochemicals segment continued to be under pressure with steady volumes and muted pricing, driven by China overcapacity In Personal Care, we are witnessing strong volume growth and increasing traction with new customers seeking outsourcing partnerships. The Nutrition segment maintained steady volumes, despite softening B3 pricing in the feed segment in last few weeks. In Semiconductors and Electronics, we are witnessing a strong growth in the new-molecule pipeline, with encouraging customer traction, particularly from Japan. Future Outlook: Our Pinnacle journey continues to progress well, reflected in strong revenue and EBITDA growth, and a robust opportunity pipeline. We remain confident of sustaining this momentum, with growth expected across all three business segments in FY27, particularly in Acetyls, where we hope to get higher volumes supported by plant closures in Europe. The new Multi-Purpose Plant remains on track for commissioning by year-end, strengthening our CDMO and Fine Chemicals growth roadmap.” Commenting on the Company’s performance, Mr. Deepak Jain, Chief Executive Officer and Managing Director, Jubilant Ingrevia Limited said: “We continued to execute well against our strategic priorities despite ongoing global uncertainties. Our diversified sourcing capabilities, strong customer partnerships, and agile operations enabled us to effectively navigate these disruptions and pricing volatility, while managing cost pass-through. This execution strength is clearly reflected in our strong performance during both Q2 and H1 FY27. We delivered another strong quarter in Q2, reinforcing our performance for H1 FY27. Revenue reached an all-time high of ₹1,394 crore in Q2 FY27, up 24% YoY, supported by stronger realizations and stable volumes. EBITDA rose 51% YoY to ₹221 crore in Q2 FY27, the highest in the last three years, while PAT increased 60% YoY to ₹111 crore. Let me share Our Segmental Business update for Q2’FY27: Specialty Chemicals 1) The business delivered a strong performance, with revenue reaching ₹560 crore, up 16% year-on-year and 5% sequentially, led by healthy volume growth across Fine Chemicals and CDMO. 2) We delivered EBITDA of ₹140 crore, translating into a strong EBITDA margin of 25%, driven by improved pricing across our value-added Fine Chemicals and CDMO portfolio. a) In Pyridine & Picolines, volumes remained stable despite continued softness in pricing. Our ongoing cost optimization and capacity debottlenecking initiatives are expected to strengthen performance going forward. b) Our Fine Chemicals business delivered broad-based growth across Pyridine and Diketene Derivatives, supported by improved pricing, with particularly strong momentum in the Diketene portfolio. c) In Personal Care, we have multiple products under development and are seeing increasing traction across key personal care segments. d) Our CDMO business continued to build strong momentum across Agro, Pharma/Personal Care and Semiconductors. i) Agro delivered healthy volume growth, led by higher Innovator CDMO volumes ii) While we are seeing strong customer engagement in Pharma with our US and Europe roadshows with innovators. iii) In Semiconductors, we continue to see growing inquiries and an expanding application pipeline, supported by our upcoming R&D and clean-room facility in Greater Noida. iv) Overall, we have 25+ confirmed molecules in our pipeline, which are expected to drive our future growth in coming years. 3) The Nutrition business segment delivered another strong quarter, with revenue reaching ₹270 crore, up 50% year-on-year and 11% sequentially. EBITDA increased to ₹39 crore, representing growth of 87% year-on-year and 9% sequentially, while margins remained healthy at 15%. a) Within Human Nutrition, Vitamin B3 delivered strong volume growth both year-on-year and sequentially, led by double-digit growth across Food and Cosmetics applications. CC/CBT also witnessed improved volumes and pricing, supported by strong customer traction across the EU, US and India. In Premixes, the Remidex integration continues to strengthen engagement and sales with Tier-1 customers in India. b) Our Animal Nutrition business also continued to show healthy momentum. Vitamin B3 delivered strong double-digit volume growth both year-on-year and sequentially, while pricing remained marginally soft. Choline maintained its domestic market position, with continued traction and sequential improvement in volumes in Europe. Premixes also delivered strong pricing improvement, supporting healthy margin performance. 4) Chemical intermediates business delivered another strong quarter, with steady volumes and improved realizations, amid higher input costs arising from elevated crude prices. a) Segment revenue grew 24% year-on-year and 8% sequentially to ₹563 crore. EBITDA rose significantly to ₹64 crore, up 226% year-on-year and 13% sequentially, driven by improved realizations across t [Showing first 8,000 characters — download PDF for full document]